MKP11093 / Mankind Pharma - LARVOL DELTA

Mankind Pharma on Monday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial for a molecule under development for the treatment of multiple autoimmune disorders. (The Economic Times) - "Developed at the Mankind Research Centre, MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile, the drug firm said in a statement...The Phase 1 trial is expected to begin shortly and will evaluate the safety, tolerability, and pharmacokinetics of MKP11093 in healthy volunteers through single and multiple-ascending dose studies, the company said."

New molecule • New P1 trial • Alopecia • Psoriasis • Rheumatoid Arthritis • Ulcerative Colitis